TWELVE-MONTH ORAL TOXICITY STUDY OF TRANDOLAPRIL (RU44570) IN RATS

The chronic toxicity of (-)-(2S, 3aR, 7aS)-1-[(S)-N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolapril: RU44570), a novel angiotensin-converting enzyme blocking antihypertensive drug, was assessed in rats by oral administration for 12 months at dosage level...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of toxicological sciences 1993/04/16, Vol.18(SupplementI), pp.37-92
Hauptverfasser: NARAMA, Isao, NAKAJIMA, Hiroo, FUJISHIMA, Hiroshi, KURIO, Wasako, MAEDA, Hiroshi, OZAKI, Kiyokazu, KUMAGAI, Yasunori, HIRAMATSU, Yasuzo, TAKABATAKE, Eigo
Format: Artikel
Sprache:eng ; jpn
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 92
container_issue SupplementI
container_start_page 37
container_title Journal of toxicological sciences
container_volume 18
creator NARAMA, Isao
NAKAJIMA, Hiroo
FUJISHIMA, Hiroshi
KURIO, Wasako
MAEDA, Hiroshi
OZAKI, Kiyokazu
KUMAGAI, Yasunori
HIRAMATSU, Yasuzo
TAKABATAKE, Eigo
description The chronic toxicity of (-)-(2S, 3aR, 7aS)-1-[(S)-N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolapril: RU44570), a novel angiotensin-converting enzyme blocking antihypertensive drug, was assessed in rats by oral administration for 12 months at dosage levels of 0.05, 0.25, 2.50 and 25.00 mg/kg/day, comparing with the control animals received 0.5% methylcellulose solution. Reversibility of the drug-induced changes was also examined by 3 months' withdrawal following the administration period. 2) There was no death or general symptom that was thought to be attributable to the administration of RU44570. 3) The body weight gain was significantly suppressed from 1st week to the end of administration period in male animals of the dosage groups of 2.50 mg/kg or more and from week 1 to 15 of administration in female animals of the 25.00 mg/kg dosage group. During the withdrawal period, the difference of the body weights between these groups and control was reduced and that was never statistically significant. 4) The food consumption generally tended to be lowered in male animals of the dosage groups of 2.50 mg/kg or more throughout the administration period. The values were significantly different from that of control group on almost all measurement points from week 2 to 34 of administration. The difference of the food consumption of these groups from control group tended to be smaller thereafter, although significant difference was seen sporadically. Male animals of the 0.05 and 0.25 mg/kg dosage groups also showed the tendency of decreased food consumption infrequently. There was no constant tendency of fluctuation in the food consumption among the each RU44570 treated group during the withdrawal period. 5) The water consumption increased significantly in male animals of the 25.00 mg/kg dosage group from 1st week to the end of administration period. Male animals of the 2.50 mg/kg dosage group showed similar high value of the water consumption but the degree was lesser than that of 25.00 mg/kg dosage group. Although female animals of the 25.00 mg/kg dosage group showed significantly increased water consumption from week 3 to 4 of administration, they began to show decreasing tendency from approximately week 10 of administration conversely. From week 26 of administration, the water consumption of this group significantly decreased frequently comparing with that of control group. Female animals of the 2.50 mg/kg dosage grou
doi_str_mv 10.2131/jts.18.SupplementI_37
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1468870121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3159123141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4027-1e7dd274801cfe1ee262b1aec6c8620a34e6bc734da63ddde6b890e5f65878883</originalsourceid><addsrcrecordid>eNplkN1PwjAUxRujQUT_BJIl-qAPw3Zd18vj5EOWTGbGQHlqStcphC_b8eB_7wiERH26uTnn3HPzQ6hJcMsjlDwuStsi0BrtttulXul1GQnKz1CdAGCXtqF9juqYAriEMnyJrqxdYOxxzPwaqgEjjGFaR0_ZWy-e9NyXZJgNnCQNYydL3qNOlE2dUTbuTp2k72RpOOwmcfiaRrFzn459n3H84ERDJw2z0TW6KOTS6pvjbKBxv5d1Bm6cPEedMHaVX_W6RPM897gPmKhCE629wJsRqVWgIPCwpL4OZopTP5cBzfO82qCNNSsCBhwAaAPdHu5uzeZrp20pFpudWVeVgvgBAMekAtNA7OBSZmOt0YXYmvlKmm9BsNiDExU4QUD8Blflmsfru9lK56fUkVSl3x11aZVcFkau1dyebJQD5dirbJODbWFL-aFPujTlXC31vpy0efD3gX__nALqUxqh1_QHzSCTug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1468870121</pqid></control><display><type>article</type><title>TWELVE-MONTH ORAL TOXICITY STUDY OF TRANDOLAPRIL (RU44570) IN RATS</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>J-STAGE (Japan Science &amp; Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>Free Full-Text Journals in Chemistry</source><creator>NARAMA, Isao ; NAKAJIMA, Hiroo ; FUJISHIMA, Hiroshi ; KURIO, Wasako ; MAEDA, Hiroshi ; OZAKI, Kiyokazu ; KUMAGAI, Yasunori ; HIRAMATSU, Yasuzo ; TAKABATAKE, Eigo</creator><creatorcontrib>NARAMA, Isao ; NAKAJIMA, Hiroo ; FUJISHIMA, Hiroshi ; KURIO, Wasako ; MAEDA, Hiroshi ; OZAKI, Kiyokazu ; KUMAGAI, Yasunori ; HIRAMATSU, Yasuzo ; TAKABATAKE, Eigo</creatorcontrib><description>The chronic toxicity of (-)-(2S, 3aR, 7aS)-1-[(S)-N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolapril: RU44570), a novel angiotensin-converting enzyme blocking antihypertensive drug, was assessed in rats by oral administration for 12 months at dosage levels of 0.05, 0.25, 2.50 and 25.00 mg/kg/day, comparing with the control animals received 0.5% methylcellulose solution. Reversibility of the drug-induced changes was also examined by 3 months' withdrawal following the administration period. 2) There was no death or general symptom that was thought to be attributable to the administration of RU44570. 3) The body weight gain was significantly suppressed from 1st week to the end of administration period in male animals of the dosage groups of 2.50 mg/kg or more and from week 1 to 15 of administration in female animals of the 25.00 mg/kg dosage group. During the withdrawal period, the difference of the body weights between these groups and control was reduced and that was never statistically significant. 4) The food consumption generally tended to be lowered in male animals of the dosage groups of 2.50 mg/kg or more throughout the administration period. The values were significantly different from that of control group on almost all measurement points from week 2 to 34 of administration. The difference of the food consumption of these groups from control group tended to be smaller thereafter, although significant difference was seen sporadically. Male animals of the 0.05 and 0.25 mg/kg dosage groups also showed the tendency of decreased food consumption infrequently. There was no constant tendency of fluctuation in the food consumption among the each RU44570 treated group during the withdrawal period. 5) The water consumption increased significantly in male animals of the 25.00 mg/kg dosage group from 1st week to the end of administration period. Male animals of the 2.50 mg/kg dosage group showed similar high value of the water consumption but the degree was lesser than that of 25.00 mg/kg dosage group. Although female animals of the 25.00 mg/kg dosage group showed significantly increased water consumption from week 3 to 4 of administration, they began to show decreasing tendency from approximately week 10 of administration conversely. From week 26 of administration, the water consumption of this group significantly decreased frequently comparing with that of control group. Female animals of the 2.50 mg/kg dosage group showed similar decrease in water consumption from approximately week 26 of administration. The value of water consumption was still high in male animals of the 25.00 mg/kg dosage group during the withdrawal period, however, reached to the level of control at week 13 of withdrawal after gradual remission. Female animals of the 0.05 mg/kg dosage group showed significant and remarkable high value in water consumption at week 1 of withdrawal. The water consumption of this group tended to increase thereafter, but the difference from that of control group was not significant. The fluctuations of water consumption in other treated groups was not observed during the withdrawal period. 6) No significant change that was thought to be attributable to the administration of RU44570 was detected by the ophthalmological examination. 7) Urinalysis revealed increased urine volume, high value of pH and the changes associated with diluted urine in male animals of the dosage groups of 0.05 mg/kg or more, i. e., lower content or value in electrolytes, bilirubine, ketone body, protein, urobilinogen, occult blood, specific gravity and number of cells in the sediment. These changes were not observed at the end of withdrawal period. 8) No drug-induced changes in kidney function were detected by PSP (Phenolsulfonphthalein) test. 9) Hematological examinations revealed significant decrease in erythrocytes counts and packed cell volume with dose dependency in male animals of the dosage groups of 2.50 m</description><identifier>ISSN: 0388-1350</identifier><identifier>EISSN: 1880-3989</identifier><identifier>DOI: 10.2131/jts.18.SupplementI_37</identifier><identifier>PMID: 8515503</identifier><identifier>CODEN: JTSCDR</identifier><language>eng ; jpn</language><publisher>Tokyo: The Japanese Society of Toxicology</publisher><subject>Administration, Oral ; Angiotensin-Converting Enzyme Inhibitors - administration &amp; dosage ; Angiotensin-Converting Enzyme Inhibitors - toxicity ; Animals ; Blood Chemical Analysis ; Drug Administration Schedule ; Female ; Hematologic Tests ; Indoles - administration &amp; dosage ; Indoles - toxicity ; Kidney - drug effects ; Kidney Function Tests ; Male ; rat ; Rats ; Rats, Sprague-Dawley ; Stomach - drug effects ; Urinalysis</subject><ispartof>The Journal of Toxicological Sciences, 1993/04/16, Vol.18(SupplementI), pp.37-92</ispartof><rights>The Japanese Society of Toxicology Headquarters</rights><rights>1994 INIST-CNRS</rights><rights>Copyright Japan Science and Technology Agency 1993</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4027-1e7dd274801cfe1ee262b1aec6c8620a34e6bc734da63ddde6b890e5f65878883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1876,4009,27902,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3783702$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8515503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NARAMA, Isao</creatorcontrib><creatorcontrib>NAKAJIMA, Hiroo</creatorcontrib><creatorcontrib>FUJISHIMA, Hiroshi</creatorcontrib><creatorcontrib>KURIO, Wasako</creatorcontrib><creatorcontrib>MAEDA, Hiroshi</creatorcontrib><creatorcontrib>OZAKI, Kiyokazu</creatorcontrib><creatorcontrib>KUMAGAI, Yasunori</creatorcontrib><creatorcontrib>HIRAMATSU, Yasuzo</creatorcontrib><creatorcontrib>TAKABATAKE, Eigo</creatorcontrib><title>TWELVE-MONTH ORAL TOXICITY STUDY OF TRANDOLAPRIL (RU44570) IN RATS</title><title>Journal of toxicological sciences</title><addtitle>J Toxicol Sci</addtitle><description>The chronic toxicity of (-)-(2S, 3aR, 7aS)-1-[(S)-N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolapril: RU44570), a novel angiotensin-converting enzyme blocking antihypertensive drug, was assessed in rats by oral administration for 12 months at dosage levels of 0.05, 0.25, 2.50 and 25.00 mg/kg/day, comparing with the control animals received 0.5% methylcellulose solution. Reversibility of the drug-induced changes was also examined by 3 months' withdrawal following the administration period. 2) There was no death or general symptom that was thought to be attributable to the administration of RU44570. 3) The body weight gain was significantly suppressed from 1st week to the end of administration period in male animals of the dosage groups of 2.50 mg/kg or more and from week 1 to 15 of administration in female animals of the 25.00 mg/kg dosage group. During the withdrawal period, the difference of the body weights between these groups and control was reduced and that was never statistically significant. 4) The food consumption generally tended to be lowered in male animals of the dosage groups of 2.50 mg/kg or more throughout the administration period. The values were significantly different from that of control group on almost all measurement points from week 2 to 34 of administration. The difference of the food consumption of these groups from control group tended to be smaller thereafter, although significant difference was seen sporadically. Male animals of the 0.05 and 0.25 mg/kg dosage groups also showed the tendency of decreased food consumption infrequently. There was no constant tendency of fluctuation in the food consumption among the each RU44570 treated group during the withdrawal period. 5) The water consumption increased significantly in male animals of the 25.00 mg/kg dosage group from 1st week to the end of administration period. Male animals of the 2.50 mg/kg dosage group showed similar high value of the water consumption but the degree was lesser than that of 25.00 mg/kg dosage group. Although female animals of the 25.00 mg/kg dosage group showed significantly increased water consumption from week 3 to 4 of administration, they began to show decreasing tendency from approximately week 10 of administration conversely. From week 26 of administration, the water consumption of this group significantly decreased frequently comparing with that of control group. Female animals of the 2.50 mg/kg dosage group showed similar decrease in water consumption from approximately week 26 of administration. The value of water consumption was still high in male animals of the 25.00 mg/kg dosage group during the withdrawal period, however, reached to the level of control at week 13 of withdrawal after gradual remission. Female animals of the 0.05 mg/kg dosage group showed significant and remarkable high value in water consumption at week 1 of withdrawal. The water consumption of this group tended to increase thereafter, but the difference from that of control group was not significant. The fluctuations of water consumption in other treated groups was not observed during the withdrawal period. 6) No significant change that was thought to be attributable to the administration of RU44570 was detected by the ophthalmological examination. 7) Urinalysis revealed increased urine volume, high value of pH and the changes associated with diluted urine in male animals of the dosage groups of 0.05 mg/kg or more, i. e., lower content or value in electrolytes, bilirubine, ketone body, protein, urobilinogen, occult blood, specific gravity and number of cells in the sediment. These changes were not observed at the end of withdrawal period. 8) No drug-induced changes in kidney function were detected by PSP (Phenolsulfonphthalein) test. 9) Hematological examinations revealed significant decrease in erythrocytes counts and packed cell volume with dose dependency in male animals of the dosage groups of 2.50 m</description><subject>Administration, Oral</subject><subject>Angiotensin-Converting Enzyme Inhibitors - administration &amp; dosage</subject><subject>Angiotensin-Converting Enzyme Inhibitors - toxicity</subject><subject>Animals</subject><subject>Blood Chemical Analysis</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Hematologic Tests</subject><subject>Indoles - administration &amp; dosage</subject><subject>Indoles - toxicity</subject><subject>Kidney - drug effects</subject><subject>Kidney Function Tests</subject><subject>Male</subject><subject>rat</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Stomach - drug effects</subject><subject>Urinalysis</subject><issn>0388-1350</issn><issn>1880-3989</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkN1PwjAUxRujQUT_BJIl-qAPw3Zd18vj5EOWTGbGQHlqStcphC_b8eB_7wiERH26uTnn3HPzQ6hJcMsjlDwuStsi0BrtttulXul1GQnKz1CdAGCXtqF9juqYAriEMnyJrqxdYOxxzPwaqgEjjGFaR0_ZWy-e9NyXZJgNnCQNYydL3qNOlE2dUTbuTp2k72RpOOwmcfiaRrFzn459n3H84ERDJw2z0TW6KOTS6pvjbKBxv5d1Bm6cPEedMHaVX_W6RPM897gPmKhCE629wJsRqVWgIPCwpL4OZopTP5cBzfO82qCNNSsCBhwAaAPdHu5uzeZrp20pFpudWVeVgvgBAMekAtNA7OBSZmOt0YXYmvlKmm9BsNiDExU4QUD8Blflmsfru9lK56fUkVSl3x11aZVcFkau1dyebJQD5dirbJODbWFL-aFPujTlXC31vpy0efD3gX__nALqUxqh1_QHzSCTug</recordid><startdate>1993</startdate><enddate>1993</enddate><creator>NARAMA, Isao</creator><creator>NAKAJIMA, Hiroo</creator><creator>FUJISHIMA, Hiroshi</creator><creator>KURIO, Wasako</creator><creator>MAEDA, Hiroshi</creator><creator>OZAKI, Kiyokazu</creator><creator>KUMAGAI, Yasunori</creator><creator>HIRAMATSU, Yasuzo</creator><creator>TAKABATAKE, Eigo</creator><general>The Japanese Society of Toxicology</general><general>Japanese Society of Toxicology</general><general>Japan Science and Technology Agency</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>7U7</scope><scope>C1K</scope><scope>SOI</scope></search><sort><creationdate>1993</creationdate><title>TWELVE-MONTH ORAL TOXICITY STUDY OF TRANDOLAPRIL (RU44570) IN RATS</title><author>NARAMA, Isao ; NAKAJIMA, Hiroo ; FUJISHIMA, Hiroshi ; KURIO, Wasako ; MAEDA, Hiroshi ; OZAKI, Kiyokazu ; KUMAGAI, Yasunori ; HIRAMATSU, Yasuzo ; TAKABATAKE, Eigo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4027-1e7dd274801cfe1ee262b1aec6c8620a34e6bc734da63ddde6b890e5f65878883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; jpn</language><creationdate>1993</creationdate><topic>Administration, Oral</topic><topic>Angiotensin-Converting Enzyme Inhibitors - administration &amp; dosage</topic><topic>Angiotensin-Converting Enzyme Inhibitors - toxicity</topic><topic>Animals</topic><topic>Blood Chemical Analysis</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Hematologic Tests</topic><topic>Indoles - administration &amp; dosage</topic><topic>Indoles - toxicity</topic><topic>Kidney - drug effects</topic><topic>Kidney Function Tests</topic><topic>Male</topic><topic>rat</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Stomach - drug effects</topic><topic>Urinalysis</topic><toplevel>online_resources</toplevel><creatorcontrib>NARAMA, Isao</creatorcontrib><creatorcontrib>NAKAJIMA, Hiroo</creatorcontrib><creatorcontrib>FUJISHIMA, Hiroshi</creatorcontrib><creatorcontrib>KURIO, Wasako</creatorcontrib><creatorcontrib>MAEDA, Hiroshi</creatorcontrib><creatorcontrib>OZAKI, Kiyokazu</creatorcontrib><creatorcontrib>KUMAGAI, Yasunori</creatorcontrib><creatorcontrib>HIRAMATSU, Yasuzo</creatorcontrib><creatorcontrib>TAKABATAKE, Eigo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Environment Abstracts</collection><jtitle>Journal of toxicological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NARAMA, Isao</au><au>NAKAJIMA, Hiroo</au><au>FUJISHIMA, Hiroshi</au><au>KURIO, Wasako</au><au>MAEDA, Hiroshi</au><au>OZAKI, Kiyokazu</au><au>KUMAGAI, Yasunori</au><au>HIRAMATSU, Yasuzo</au><au>TAKABATAKE, Eigo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TWELVE-MONTH ORAL TOXICITY STUDY OF TRANDOLAPRIL (RU44570) IN RATS</atitle><jtitle>Journal of toxicological sciences</jtitle><addtitle>J Toxicol Sci</addtitle><date>1993</date><risdate>1993</risdate><volume>18</volume><issue>SupplementI</issue><spage>37</spage><epage>92</epage><pages>37-92</pages><issn>0388-1350</issn><eissn>1880-3989</eissn><coden>JTSCDR</coden><abstract>The chronic toxicity of (-)-(2S, 3aR, 7aS)-1-[(S)-N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolapril: RU44570), a novel angiotensin-converting enzyme blocking antihypertensive drug, was assessed in rats by oral administration for 12 months at dosage levels of 0.05, 0.25, 2.50 and 25.00 mg/kg/day, comparing with the control animals received 0.5% methylcellulose solution. Reversibility of the drug-induced changes was also examined by 3 months' withdrawal following the administration period. 2) There was no death or general symptom that was thought to be attributable to the administration of RU44570. 3) The body weight gain was significantly suppressed from 1st week to the end of administration period in male animals of the dosage groups of 2.50 mg/kg or more and from week 1 to 15 of administration in female animals of the 25.00 mg/kg dosage group. During the withdrawal period, the difference of the body weights between these groups and control was reduced and that was never statistically significant. 4) The food consumption generally tended to be lowered in male animals of the dosage groups of 2.50 mg/kg or more throughout the administration period. The values were significantly different from that of control group on almost all measurement points from week 2 to 34 of administration. The difference of the food consumption of these groups from control group tended to be smaller thereafter, although significant difference was seen sporadically. Male animals of the 0.05 and 0.25 mg/kg dosage groups also showed the tendency of decreased food consumption infrequently. There was no constant tendency of fluctuation in the food consumption among the each RU44570 treated group during the withdrawal period. 5) The water consumption increased significantly in male animals of the 25.00 mg/kg dosage group from 1st week to the end of administration period. Male animals of the 2.50 mg/kg dosage group showed similar high value of the water consumption but the degree was lesser than that of 25.00 mg/kg dosage group. Although female animals of the 25.00 mg/kg dosage group showed significantly increased water consumption from week 3 to 4 of administration, they began to show decreasing tendency from approximately week 10 of administration conversely. From week 26 of administration, the water consumption of this group significantly decreased frequently comparing with that of control group. Female animals of the 2.50 mg/kg dosage group showed similar decrease in water consumption from approximately week 26 of administration. The value of water consumption was still high in male animals of the 25.00 mg/kg dosage group during the withdrawal period, however, reached to the level of control at week 13 of withdrawal after gradual remission. Female animals of the 0.05 mg/kg dosage group showed significant and remarkable high value in water consumption at week 1 of withdrawal. The water consumption of this group tended to increase thereafter, but the difference from that of control group was not significant. The fluctuations of water consumption in other treated groups was not observed during the withdrawal period. 6) No significant change that was thought to be attributable to the administration of RU44570 was detected by the ophthalmological examination. 7) Urinalysis revealed increased urine volume, high value of pH and the changes associated with diluted urine in male animals of the dosage groups of 0.05 mg/kg or more, i. e., lower content or value in electrolytes, bilirubine, ketone body, protein, urobilinogen, occult blood, specific gravity and number of cells in the sediment. These changes were not observed at the end of withdrawal period. 8) No drug-induced changes in kidney function were detected by PSP (Phenolsulfonphthalein) test. 9) Hematological examinations revealed significant decrease in erythrocytes counts and packed cell volume with dose dependency in male animals of the dosage groups of 2.50 m</abstract><cop>Tokyo</cop><pub>The Japanese Society of Toxicology</pub><pmid>8515503</pmid><doi>10.2131/jts.18.SupplementI_37</doi><tpages>56</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0388-1350
ispartof The Journal of Toxicological Sciences, 1993/04/16, Vol.18(SupplementI), pp.37-92
issn 0388-1350
1880-3989
language eng ; jpn
recordid cdi_proquest_journals_1468870121
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; Free Full-Text Journals in Chemistry
subjects Administration, Oral
Angiotensin-Converting Enzyme Inhibitors - administration & dosage
Angiotensin-Converting Enzyme Inhibitors - toxicity
Animals
Blood Chemical Analysis
Drug Administration Schedule
Female
Hematologic Tests
Indoles - administration & dosage
Indoles - toxicity
Kidney - drug effects
Kidney Function Tests
Male
rat
Rats
Rats, Sprague-Dawley
Stomach - drug effects
Urinalysis
title TWELVE-MONTH ORAL TOXICITY STUDY OF TRANDOLAPRIL (RU44570) IN RATS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T03%3A58%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TWELVE-MONTH%20ORAL%20TOXICITY%20STUDY%20OF%20TRANDOLAPRIL%20(RU44570)%20IN%20RATS&rft.jtitle=Journal%20of%20toxicological%20sciences&rft.au=NARAMA,%20Isao&rft.date=1993&rft.volume=18&rft.issue=SupplementI&rft.spage=37&rft.epage=92&rft.pages=37-92&rft.issn=0388-1350&rft.eissn=1880-3989&rft.coden=JTSCDR&rft_id=info:doi/10.2131/jts.18.SupplementI_37&rft_dat=%3Cproquest_cross%3E3159123141%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1468870121&rft_id=info:pmid/8515503&rfr_iscdi=true